Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave - Report - MDSpire
Advertisement
Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave
Clinical Features and Antibody Responses to Omicron Variants in Pregnant Women
Overview
This study investigates the clinical characteristics and antibody responses in pregnant women infected with the Omicron variant of SARS-CoV-2 during a surge in China. Key findings indicate prolonged symptom recovery in pregnant women compared to non-pregnant controls, alongside reduced neutralizing antibody levels against the XBB.1.5 subvariant.
Background
Understanding the impact of SARS-CoV-2 infection on pregnant women is crucial, as they are considered a vulnerable population. The immune response and clinical outcomes in this group can inform management strategies and vaccination recommendations.
Data Highlights
Parameter
Pregnant Women
Non-Pregnant Controls
Symptom recovery > 1 week
73.0%
23.1%
Medical consultation rate
73.0%
15.4%
XBB.1.5 neutralizing antibody titers
16.35
45.96
Key Findings
Pregnant women had prolonged symptom recovery compared to non-pregnant women (73.0% vs. 23.1%, P = 0.045).
Higher medical consultation rates were observed in pregnant women (73.0% vs. 15.4%, P < 0.001).
No significant differences in clinical manifestations were found across different trimesters of pregnancy.
Neutralizing antibody levels against Omicron BA.4/5 showed no intergroup difference.
Pregnant women exhibited significantly lower XBB.1.5 neutralizing antibody titers compared to controls (P < 0.05).
Clinical Implications
The findings highlight the need for careful monitoring of pregnant women with COVID-19, particularly regarding symptom management and potential antibody response issues. Clinicians should be aware of the prolonged recovery times and lower neutralizing antibody levels in this population.
Conclusion
This study underscores the unique clinical challenges faced by pregnant women during SARS-CoV-2 Omicron infections, particularly in terms of symptom recovery and immune response. Further research is warranted to optimize care for this vulnerable group.
